FEDERICO
PULIDO ORTEGA

Profesor asociado de Ciencias de la Salud

Foto de FEDERICO

Foto de Orlando Immunology Center

Orlando Immunology Center

Orlando, Estados Unidos

Publications in collaboration with researchers from Orlando Immunology Center (3)

2020

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial
The Lancet HIV, Vol. 7, Núm. 1, pp. e16-e26

2019

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
Antiviral Research, Vol. 170

2018

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
The Lancet HIV, Vol. 5, Núm. 5, pp. e211-e220